A group of new and existing backers have provided cash to Galecto, based on research from the universities of Lund and Edinburgh.
US-based cancer and fibrosis treatment developer Galecto completed a $64m funding round on Friday backed by pharmaceutical firms Novo and Bristol Myers-Squibb (BMS).
Soleus Capital and Eir Ventures co-led the round, while Cormorant Asset Management, Janus Henderson Investors, Hadean Ventures, Sphera, Asymmetry Capital Management, Canica, OrbiMed, Ysios Capital, HBM Healthcare Investments, Sunstone Capital, Seventure and Maverick Ventures also took part.
Founded in 2011, Galecto is working on drugs that target galectins, a group of proteins involved in diseases…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
